NetraMark Holdings Inc. (TSX: AIAI | OTCQB: AINMF) | LIVE INVESTOR BRIEF — May 8, 2026 — 12:37 PM ET | CONFIDENTIAL
LIVE INVESTOR BRIEF — MAY 8, 2026 — 12:37 PM ET
NetraMark Holdings Inc.
TSX: AIAI | OTCQB: AINMF | Frankfurt: PF0
Price Action, Volume Surge & Pre-Earnings Setup — 5 Days to Q1 FY26 Results
Price (12:37 PM ET)
$1.03 CAD
Up $0.06 (+6.2%)
Intraday high
$1.09 CAD
~+12% from open
Intraday low
$1.00 CAD
$1.00 held as support
VWAP
$1.03 CAD
Price at VWAP = buyers dominant
TSX volume (live)
145,233
37,759 avg — 3.85× normal
Market cap
$95.43M CAD
Back above $95M
Shares outstanding
92.65M
Post-placement float
52-week high
$1.12 CAD
Within striking distance
52-week low
$0.68 CAD
Stock has recovered 51%
Cash / Equiv
$1.41M CAD
Plus warrants at $1.35
Zacks USD target
$2.25 USD
38x P/S on $8–10M backlog
Days to earnings
5 days
May 13 — Q1 FY26
Section 1 — Today's Price Action: What the Numbers Say
The volume is the story
At 145,233 TSX shares traded by 12:37 PM ET — with 3 hours and 23 minutes remaining — today's session has already produced 3.85× the 37,759 daily average. At the current pace, total daily volume is tracking toward 200,000–250,000 shares. That would represent one of the highest single-day volume readings since the TSX uplisting in February 2026.
Volume thresholds — where today sits
Daily average
37,759
80K — new attention
80,000
150K — institutional
150,000
TODAY (12:37 PM)
145,233 ▶
End-of-day est.
200–250K
THRESHOLD STATUS
Today's volume of 145,233 TSX shares (3h23m remaining) is approaching the 150,000 institutional interest threshold identified in our May 5 investor brief. At the current intraday pace, end-of-day volume is tracking 200,000–250,000 — which would comfortably exceed the institutional threshold and represent a structural shift in daily liquidity for AIAI.
The $1.00 support level
Today's intraday low was exactly $1.00 CAD — the private placement price from January 2026 at which 3.5 million units were issued to placees. This level has now acted as confirmed technical support. The stock hit $1.09 at the open, pulled back to test $1.00, found buyers there, and is holding $1.03 at VWAP. In micro-cap technical analysis, a VWAP close on a high-volume day with key level support intact is a constructive setup.
Section 2 — What Drove Today's Move
There is no single material press release that directly triggered today's 12% intraday pop. The move reflects the convergence of four separate forces compressing into a 5-day earnings window:
Factor
Weight
Analysis
Earnings pre-positioning
Primary
May 13 Q1 FY26 earnings are 5 days away. Informed buyers accumulating before what they expect to be a material revenue and backlog update. Standard pre-catalyst positioning behaviour in thinly traded micro-caps.
Lawrence Guy board departure
Significant
Guy resigned May 7 citing personal reasons. He was the subject of an OSC enforcement matter announced April 2026. His departure removes a governance overhang heading into an institutional-facing earnings report. The market is reading this as governance cleanup — positive.
Accumulated awareness
Contributing
TSX bell ringing (May 5), CMO appointment (May 4), Theocharous article (May 5), Zacks $2.25 target, investor brief circulation on InvestorsHangout — compound awareness building over 5 days translating into delayed price response.
Broader market recovery
Minor
TSX recovering from April tariff selloff. Small-caps disproportionately punished in April tend to bounce harder in recovery. Context, not cause.
Section 3 — The Pre-Earnings Setup: May 13
With 5 days to Q1 FY26 earnings, the setup is the strongest it has been since the October 2025 highs. The stock has recovered from $0.68 (52-week low) to $1.03 — a 51% recovery — on the highest volume in months. The question is whether May 13 delivers the fundamental catalyst to sustain and extend this move.
The three questions that define the earnings response
QUESTION 1
REVENUE: Q1 FY26 actual revenue was C$118,853 (confirmed by Zacks SCR). FY25 full-year was C$432,495. With the Worldwide Clinical Trials channel (60+ countries) commercially live since October 2025 and contracts averaging US$200–300K each, Q2 FY26 should show material progress. Any step-up above C$150–200K for Q2 would confirm the channel is converting. A surprise above C$300K would be transformational.
QUESTION 2
BACKLOG UPDATE: The C$2.5M backlog stated at December 2025 with a target of C$8–10M by mid-2026 is the single most important number for validating the Zacks $2.25 price target. The Zacks methodology applies 38x P/S to C$9M (midpoint) — every update toward that target directly validates the valuation. A backlog update of C$3.5–4M+ would constitute a material positive surprise.
QUESTION 3
NEW VERTICALS: Any commentary on cell therapy (Dr. Theocharous's network, 10,373 active global trials), European market contracts (Dr. Theocharous's EMA-facing relationships, zero disclosed European contracts to date), Paradox Risk Score (Pentara collaboration), or Worldwide pipeline specifics would signal the next phase of commercial expansion — and open an entirely new investor audience.
Milestone recap — what the earnings report follows
Date
Milestone since last earnings update
Feb 13
TSX uplisting — institutional investor access unlocked
Feb 19
$3.5M private placement fully closed — 12-month runway secured
Mar 11
Phase 2 depression contract — global biopharmaceutical company (Zacks confirmed)
Mar 19
AD/PD 2026 — A4 Alzheimer's trial findings presented at world's premier Alzheimer's conference
Mar 25
FMP/ROME oncology collaboration — precision oncology Phase II dataset (dual platform value)
Apr 9
Frontiers in Pharmacology peer-reviewed publication — psychedelic therapeutics framework
Apr 18–22
U.S. Executive Order on psychedelic therapeutics — NetraMark published scientific framework 9 days prior
Apr 20
Zacks SCR initiates coverage — $2.25 USD price target, 38x P/S on backlog, 85% confidence discount
May 4
Dr. Theocharous appointed Fractional CMO — 35yr cell & gene therapy pioneer, Worldwide CRO's own advisor
May 5
TSX opening bell ceremony — Worldwide article by Dr. Theocharous to 221,631 followers naming AI operational planning
May 7
Lawrence Guy resigns from Board — OSC-related governance overhang removed ahead of institutional earnings report
May 8 TODAY
$1.03 CAD, +6.2%, 145K+ shares — 3.85× average volume, $1.00 support confirmed, market cap $95.43M
May 13 ►
Q1 FY26 EARNINGS — Primary re-rating catalyst. Revenue progress, backlog update, new vertical commentary.
Section 4 — Earnings Scenarios: What Happens If…
BULL SCENARIO
Revenue materially above $150K for Q2, backlog updated toward $4M+, any new contract announcement or cell therapy / European commentary. Stock response: +20–40% on the day, with sustained follow-through as the Zacks $2.25 target becomes the reference point for new investors discovering the name. Volume could sustain above 100K/day for the following week.
BASE SCENARIO
Revenue shows modest progress ($120–150K), backlog edges higher but no dramatic update, no new verticals announced. Stock response: flat to +8%, with the conversation shifting to the $8–10M backlog timeline and when the Worldwide channel truly inflects. Consolidation around $1.00–$1.10 for the week following.
BEAR SCENARIO
Revenue flat or below Q1 ($118K), no backlog update, no new contracts. Stock response: -10–15% giveback, testing $0.90 support. The fundamental case remains intact but timeline extends. Note: a bear earnings scenario does NOT invalidate the Zacks target — it delays it. The business has not deteriorated; the backlog conversion has simply taken longer than the mid-2026 timeline implied.
Section 5 — Investor Summary
THE SITUATION
NetraMark is trading at $1.03 CAD on 145,000+ TSX shares — its highest volume session in months — five days before its most consequential earnings report since the TSX uplisting. The stock has recovered 51% from its 52-week low of $0.68. The $1.00 private placement reference price has held as confirmed technical support. The governance overhang from the Lawrence Guy OSC matter has been resolved. The Zacks $2.25 USD price target sits 160% above today's price. May 13 is when everything either confirms or defers.
THE OPPORTUNITY
At $95.43M market cap, NetraMark is valued at approximately $0.72 per dollar of Zacks-implied fair value. The discount is structural: institutional awareness is still limited despite the TSX listing, analyst coverage is single-firm (Zacks only), and the cell therapy / European verticals signalled by the Theocharous appointment have not yet been formally announced. All three of these constraints will resolve over the next 60–90 days.
LIVE INVESTOR BRIEF — MAY 8, 2026 — 12:37 PM ET
NetraMark Holdings Inc.
TSX: AIAI | OTCQB: AINMF | Frankfurt: PF0
Price Action, Volume Surge & Pre-Earnings Setup — 5 Days to Q1 FY26 Results
Price (12:37 PM ET)
$1.03 CAD
Up $0.06 (+6.2%)
Intraday high
$1.09 CAD
~+12% from open
Intraday low
$1.00 CAD
$1.00 held as support
VWAP
$1.03 CAD
Price at VWAP = buyers dominant
TSX volume (live)
145,233
37,759 avg — 3.85× normal
Market cap
$95.43M CAD
Back above $95M
Shares outstanding
92.65M
Post-placement float
52-week high
$1.12 CAD
Within striking distance
52-week low
$0.68 CAD
Stock has recovered 51%
Cash / Equiv
$1.41M CAD
Plus warrants at $1.35
Zacks USD target
$2.25 USD
38x P/S on $8–10M backlog
Days to earnings
5 days
May 13 — Q1 FY26
Section 1 — Today's Price Action: What the Numbers Say
The volume is the story
At 145,233 TSX shares traded by 12:37 PM ET — with 3 hours and 23 minutes remaining — today's session has already produced 3.85× the 37,759 daily average. At the current pace, total daily volume is tracking toward 200,000–250,000 shares. That would represent one of the highest single-day volume readings since the TSX uplisting in February 2026.
Volume thresholds — where today sits
Daily average
37,759
80K — new attention
80,000
150K — institutional
150,000
TODAY (12:37 PM)
145,233 ▶
End-of-day est.
200–250K
THRESHOLD STATUS
Today's volume of 145,233 TSX shares (3h23m remaining) is approaching the 150,000 institutional interest threshold identified in our May 5 investor brief. At the current intraday pace, end-of-day volume is tracking 200,000–250,000 — which would comfortably exceed the institutional threshold and represent a structural shift in daily liquidity for AIAI.
The $1.00 support level
Today's intraday low was exactly $1.00 CAD — the private placement price from January 2026 at which 3.5 million units were issued to placees. This level has now acted as confirmed technical support. The stock hit $1.09 at the open, pulled back to test $1.00, found buyers there, and is holding $1.03 at VWAP. In micro-cap technical analysis, a VWAP close on a high-volume day with key level support intact is a constructive setup.
Section 2 — What Drove Today's Move
There is no single material press release that directly triggered today's 12% intraday pop. The move reflects the convergence of four separate forces compressing into a 5-day earnings window:
Factor
Weight
Analysis
Earnings pre-positioning
Primary
May 13 Q1 FY26 earnings are 5 days away. Informed buyers accumulating before what they expect to be a material revenue and backlog update. Standard pre-catalyst positioning behaviour in thinly traded micro-caps.
Lawrence Guy board departure
Significant
Guy resigned May 7 citing personal reasons. He was the subject of an OSC enforcement matter announced April 2026. His departure removes a governance overhang heading into an institutional-facing earnings report. The market is reading this as governance cleanup — positive.
Accumulated awareness
Contributing
TSX bell ringing (May 5), CMO appointment (May 4), Theocharous article (May 5), Zacks $2.25 target, investor brief circulation on InvestorsHangout — compound awareness building over 5 days translating into delayed price response.
Broader market recovery
Minor
TSX recovering from April tariff selloff. Small-caps disproportionately punished in April tend to bounce harder in recovery. Context, not cause.
Section 3 — The Pre-Earnings Setup: May 13
With 5 days to Q1 FY26 earnings, the setup is the strongest it has been since the October 2025 highs. The stock has recovered from $0.68 (52-week low) to $1.03 — a 51% recovery — on the highest volume in months. The question is whether May 13 delivers the fundamental catalyst to sustain and extend this move.
The three questions that define the earnings response
QUESTION 1
REVENUE: Q1 FY26 actual revenue was C$118,853 (confirmed by Zacks SCR). FY25 full-year was C$432,495. With the Worldwide Clinical Trials channel (60+ countries) commercially live since October 2025 and contracts averaging US$200–300K each, Q2 FY26 should show material progress. Any step-up above C$150–200K for Q2 would confirm the channel is converting. A surprise above C$300K would be transformational.
QUESTION 2
BACKLOG UPDATE: The C$2.5M backlog stated at December 2025 with a target of C$8–10M by mid-2026 is the single most important number for validating the Zacks $2.25 price target. The Zacks methodology applies 38x P/S to C$9M (midpoint) — every update toward that target directly validates the valuation. A backlog update of C$3.5–4M+ would constitute a material positive surprise.
QUESTION 3
NEW VERTICALS: Any commentary on cell therapy (Dr. Theocharous's network, 10,373 active global trials), European market contracts (Dr. Theocharous's EMA-facing relationships, zero disclosed European contracts to date), Paradox Risk Score (Pentara collaboration), or Worldwide pipeline specifics would signal the next phase of commercial expansion — and open an entirely new investor audience.
Milestone recap — what the earnings report follows
Date
Milestone since last earnings update
Feb 13
TSX uplisting — institutional investor access unlocked
Feb 19
$3.5M private placement fully closed — 12-month runway secured
Mar 11
Phase 2 depression contract — global biopharmaceutical company (Zacks confirmed)
Mar 19
AD/PD 2026 — A4 Alzheimer's trial findings presented at world's premier Alzheimer's conference
Mar 25
FMP/ROME oncology collaboration — precision oncology Phase II dataset (dual platform value)
Apr 9
Frontiers in Pharmacology peer-reviewed publication — psychedelic therapeutics framework
Apr 18–22
U.S. Executive Order on psychedelic therapeutics — NetraMark published scientific framework 9 days prior
Apr 20
Zacks SCR initiates coverage — $2.25 USD price target, 38x P/S on backlog, 85% confidence discount
May 4
Dr. Theocharous appointed Fractional CMO — 35yr cell & gene therapy pioneer, Worldwide CRO's own advisor
May 5
TSX opening bell ceremony — Worldwide article by Dr. Theocharous to 221,631 followers naming AI operational planning
May 7
Lawrence Guy resigns from Board — OSC-related governance overhang removed ahead of institutional earnings report
May 8 TODAY
$1.03 CAD, +6.2%, 145K+ shares — 3.85× average volume, $1.00 support confirmed, market cap $95.43M
May 13 ►
Q1 FY26 EARNINGS — Primary re-rating catalyst. Revenue progress, backlog update, new vertical commentary.
Section 4 — Earnings Scenarios: What Happens If…
BULL SCENARIO
Revenue materially above $150K for Q2, backlog updated toward $4M+, any new contract announcement or cell therapy / European commentary. Stock response: +20–40% on the day, with sustained follow-through as the Zacks $2.25 target becomes the reference point for new investors discovering the name. Volume could sustain above 100K/day for the following week.
BASE SCENARIO
Revenue shows modest progress ($120–150K), backlog edges higher but no dramatic update, no new verticals announced. Stock response: flat to +8%, with the conversation shifting to the $8–10M backlog timeline and when the Worldwide channel truly inflects. Consolidation around $1.00–$1.10 for the week following.
BEAR SCENARIO
Revenue flat or below Q1 ($118K), no backlog update, no new contracts. Stock response: -10–15% giveback, testing $0.90 support. The fundamental case remains intact but timeline extends. Note: a bear earnings scenario does NOT invalidate the Zacks target — it delays it. The business has not deteriorated; the backlog conversion has simply taken longer than the mid-2026 timeline implied.
Section 5 — Investor Summary
THE SITUATION
NetraMark is trading at $1.03 CAD on 145,000+ TSX shares — its highest volume session in months — five days before its most consequential earnings report since the TSX uplisting. The stock has recovered 51% from its 52-week low of $0.68. The $1.00 private placement reference price has held as confirmed technical support. The governance overhang from the Lawrence Guy OSC matter has been resolved. The Zacks $2.25 USD price target sits 160% above today's price. May 13 is when everything either confirms or defers.
THE OPPORTUNITY
At $95.43M market cap, NetraMark is valued at approximately $0.72 per dollar of Zacks-implied fair value. The discount is structural: institutional awareness is still limited despite the TSX listing, analyst coverage is single-firm (Zacks only), and the cell therapy / European verticals signalled by the Theocharous appointment have not yet been formally announced. All three of these constraints will resolve over the next 60–90 days.
